Preeclampsia: pathophysiology and emerging treatments
Preeclampsia is a pregnancy-specific hypertensive disorder that can affect nearly every organ system. It is commonly identified through new-onset hypertension after 20 weeks of gestation, with proteinuria or other signs of maternal organ dysfunction. The condition may develop gradually, or it may progress rapidly into severe disease involving the brain, liver, kidneys, lungs, blood, or placenta.
Its biological origins begin much earlier than the clinical diagnosis. Abnormal placental development, impaired remodeling of the uterine arteries, maternal immune responses, oxidative stress, and endothelial injury interact in complex ways. This helps explain why preeclampsia presents in different forms and why a single treatment has not yet replaced delivery of the placenta as the definitive cure.
Research discussed across perinatal and neonatal medicine continues to refine risk prediction, monitoring, and treatment. The experience of the FAOPS 2020 congress, which was planned in Tokyo before cancellation during the COVID-19 pandemic, also reflects how rapidly maternal care must adapt when scientific priorities and health systems are disrupted.
How preeclampsia begins in the placenta
In a healthy pregnancy, extravillous trophoblasts migrate into the maternal decidua and remodel spiral arteries. These vessels become wider and less responsive to vasoconstrictive signals, allowing a consistent, low-resistance blood supply to the placenta. In preeclampsia, this transformation is often incomplete. The placenta may receive an intermittent or relatively reduced blood flow, producing cycles of ischemia and reperfusion.
The stressed placenta releases a range of circulating factors into the maternal bloodstream. Two of the most studied are soluble fms-like tyrosine kinase-1, or sFlt-1, and soluble endoglin. These antiangiogenic proteins interfere with vascular endothelial growth factor and transforming growth factor beta signaling. As proangiogenic support declines, the maternal endothelium becomes more permeable and less able to regulate vascular tone.
This placental theory does not mean that every case follows an identical pathway. Early-onset disease is more strongly associated with placental dysfunction, fetal growth restriction, and abnormal uterine artery Doppler findings. Late-onset preeclampsia may arise when a placenta with less dramatic structural impairment meets a maternal circulation that has limited cardiovascular or metabolic reserve.
Why maternal organs become vulnerable
Endothelial dysfunction is central to the clinical syndrome. Injured endothelial cells promote vasoconstriction, platelet activation, inflammation, and leakage of fluid into surrounding tissues. The result can include high blood pressure, proteinuria from glomerular endotheliosis, elevated liver enzymes, low platelet counts, pulmonary edema, and neurological symptoms such as headache or visual disturbance.
The maternal immune system also contributes. Pregnancy requires carefully regulated tolerance between maternal tissues and fetal-placental antigens. Abnormal natural killer cell activity, altered cytokine profiles, complement activation, and maladaptation at the maternal-fetal interface may affect placental invasion. Genetic predisposition, previous preeclampsia, autoimmune disease, chronic hypertension, diabetes, obesity, kidney disease, and multifetal pregnancy can further increase risk.
Preeclampsia can overlap with other hypertensive disorders, so diagnosis depends on careful assessment rather than blood pressure alone. Severe features include very high or persistent hypertension, thrombocytopenia, worsening renal function, impaired liver function, pulmonary edema, or persistent cerebral or visual symptoms. Eclampsia refers to seizures associated with the disease and requires immediate emergency management.
Detecting risk before severe disease
Prediction is moving toward a combined model rather than reliance on one symptom or test. A useful assessment may include maternal characteristics, medical history, mean arterial pressure, uterine artery pulsatility index, and biochemical markers such as placental growth factor. The sFlt-1-to-placental growth factor ratio can help assess the likelihood of short-term progression in selected patients, although availability, local protocols, and gestational age affect interpretation.
Low-dose aspirin is an established preventive option for people at high risk when started early in pregnancy, commonly before 16 weeks and under clinician guidance. Calcium supplementation may reduce risk in populations with low dietary calcium intake. These measures do not eliminate preeclampsia, and they should be combined with appropriate prenatal visits, blood pressure monitoring, and evaluation of fetal growth.
Antenatal care has also changed in practical ways. Remote consultations, home blood pressure devices, digital symptom reporting, and centralized maternity assessment can support patients who live far from specialist services. The pandemic accelerated these approaches, as described in reporting on antenatal care changes, while also showing that technology cannot replace urgent in-person examination when warning signs appear.
Current treatment and the timing of birth
Management depends on gestational age, disease severity, maternal symptoms, laboratory findings, fetal condition, and access to obstetric and neonatal care. Mild disease without severe features may be managed with frequent blood pressure checks, laboratory testing, fetal surveillance, and education about symptoms that require immediate review. The goal is to prolong pregnancy safely while avoiding sudden maternal deterioration.
Antihypertensive medication is used to reduce the risk of stroke and other complications. Commonly used agents include labetalol, nifedipine, and methyldopa, depending on local practice and individual circumstances. Acute severe hypertension requires prompt treatment, because the danger is related to the intensity and duration of elevated pressure rather than to a single reading viewed in isolation.
Magnesium sulfate is used for seizure prevention in patients with severe features and for treatment of eclampsia. It does not lower blood pressure or reverse placental disease, but it reduces the risk of seizures when appropriately administered and monitored. Corticosteroids may be given when preterm birth is likely to improve fetal lung maturity, with additional neonatal planning when delivery is expected very early.
Delivery remains the definitive treatment because the placenta drives the disease process. Yet birth is not always an immediate cure: hypertension and laboratory abnormalities can persist or worsen during the postpartum period. Patients need a discharge plan, blood pressure follow-up, medication review, and clear instructions about headache, vision changes, chest pain, shortness of breath, severe abdominal pain, or seizures.
| Clinical situation | Main priorities | Potential approach |
|---|---|---|
| High risk without diagnosed disease | Prevention and surveillance | Aspirin when indicated, calcium assessment, blood pressure and fetal-growth monitoring |
| Preeclampsia without severe features | Assess progression and fetal wellbeing | Regular laboratory tests, symptom review, blood pressure checks, and planned delivery based on findings |
| Severe hypertension or severe features | Prevent stroke, seizures, organ injury, and fetal compromise | Urgent antihypertensive therapy, magnesium sulfate when indicated, corticosteroids if preterm birth is likely |
| Eclampsia or major maternal instability | Emergency stabilization | Airway and seizure management, magnesium sulfate, blood pressure control, and expedited birth |
| Postpartum hypertension | Detect delayed deterioration | Home or clinic monitoring, medication adjustment, and urgent review of warning symptoms |
Therapies being investigated
Emerging treatments aim to interrupt the molecular pathways that connect placental stress with maternal endothelial injury. One strategy is removal of circulating sFlt-1 through apheresis. Early studies suggest that lowering this antiangiogenic factor may improve maternal laboratory findings or prolong pregnancy in carefully selected cases, but the intervention is specialized and has not become routine therapy.
Other approaches include engineered nanoparticles, small interfering RNA, and targeted drug delivery designed to reduce placental production of antiangiogenic proteins. Researchers are also studying agents that influence nitric oxide signaling, oxidative stress, mitochondrial function, complement activation, and vascular inflammation. These therapies face a high safety threshold because any medication must protect the mother without harming the fetus or placenta.
Biomarker-guided care may arrive before a new disease-modifying drug. Measuring angiogenic balance, endothelial injury, inflammatory activity, and placental function could help clinicians distinguish patients likely to remain stable from those at risk of rapid progression. Such tools may reduce unnecessary early delivery while ensuring that severe disease is recognized before catastrophic complications occur.
The most promising future is likely to combine several modest advances: earlier risk classification, better home monitoring, more precise referral, and therapies targeted to a patient’s dominant biological pathway. Large, diverse trials are essential because preeclampsia varies by ethnicity, healthcare setting, gestational age, and underlying maternal health.
Maternal and newborn care beyond delivery
Preeclampsia has consequences that extend beyond the pregnancy. People who experience it have a higher lifetime risk of chronic hypertension, ischemic heart disease, stroke, heart failure, kidney disease, and type 2 diabetes. A postpartum transition plan should therefore include cardiovascular risk assessment, healthy blood pressure targets, support for physical recovery, and communication with primary care.
The newborn may face prematurity, fetal growth restriction, placental insufficiency, or complications related to an urgent birth. Neonatal teams should prepare for respiratory support, temperature regulation, feeding difficulties, hypoglycemia, and longer hospital stays when delivery occurs early. Coordinated counseling helps families understand why birth may be recommended even when the fetus is still developing.
Breastfeeding remains possible for many mothers with hypertensive disorders, including those recovering from infection or receiving compatible medications. Practical support matters when illness, separation, fatigue, or hospitalization interferes with feeding; clinical resources on breastfeeding guidance illustrate how maternal and neonatal care can be adapted during public health emergencies.
Priorities for safer care
Effective management depends on combining evidence-based treatment with reliable communication. Patients should know their baseline blood pressure, understand the purpose of prescribed medication, and receive written guidance about when to contact maternity services. Clinicians need protocols that support rapid escalation rather than forcing families to navigate fragmented systems during an emergency.
Research and service planning should focus on the following priorities:
- Expand access to validated blood pressure devices and clear home-monitoring instructions.
- Use angiogenic biomarkers and uterine artery assessment where local expertise and resources support them.
- Strengthen referral pathways between community maternity services, obstetric specialists, anesthesiology, and neonatal teams.
- Include postpartum cardiovascular follow-up as a standard part of preeclampsia care.
- Recruit diverse participants into trials of preventive, diagnostic, and disease-modifying therapies.
Professional collaboration remains especially important in perinatal medicine, where obstetric, neonatal, cardiology, nephrology, and laboratory teams often contribute to one case. The scientific and educational record associated with the FAOPS 2020 congress reflects this multidisciplinary focus, even though the planned meeting could not take place.
Better outcomes will come from recognizing that preeclampsia is a syndrome rather than a single disease. Clinicians can act now through prevention, timely diagnosis, blood pressure control, seizure prophylaxis, thoughtful delivery planning, and structured postpartum follow-up, while research continues toward treatments that address placental and vascular biology directly.
Patients with possible preeclampsia should seek urgent maternity assessment for severe headache, visual changes, sudden swelling, upper abdominal pain, breathlessness, reduced fetal movement, or a markedly elevated blood pressure. Healthcare professionals can strengthen local protocols, review emerging evidence, and build coordinated pathways that protect both parent and baby from the earliest warning sign through long-term follow-up.
